Information Provided By: 
Fly News Breaks for June 26, 2017
HSTM
Jun 26, 2017 | 12:27 EDT
Baird analyst Matthew Gillmor said his "instinct" is to buy the weakness in shares of HealthStream after the company announced it will not renew its agreement with Laerdal, as he notes the potential P&L impact seems manageable and will be spread over 2019-2021 while he believes the company will be able to replace HeartCode/RQI with new and better products. The analyst, who also thinks HealthStream is set up for a better than expected Q2 report, keeps an Outperform rating and $35 price target on the shares.
News For HSTM From the Last 2 Days
There are no results for your query HSTM
